Developer docs
API playgroundTry for free, no card

Search company profiles

ISA Pharmaceuticals

Full company profile

uuid0002ilt

Namestring
ISA Pharmaceuticals
Legal namestring
ISA Pharmaceuticals B.V.
Websiteurl
isa-pharma.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

ISA Pharmaceuticals B.V. is a privately held, clinical-stage Dutch biotechnology company founded in 2004 in Leiden (headquartered in Oegstgeest at the Leiden Bio Science Park) that develops rationally designed synthetic therapeutic vaccines for cancer and persistent viral infections. Its product engine rests on two proprietary platforms: the Synthetic Long Peptide (SLP®) technology — which delivers peptide vaccines covering the most immunogenic regions of target antigens and induces both CD4+ and CD8+ T-cell responses regardless of HLA type — and the AMPLIVANT® toll-like receptor (TLR) ligand adjuvant, which enhances dendritic cell targeting and is reported to be roughly 100-fold more potent than reference adjuvants. The clinical pipeline comprises four core programs (ISA101b for HPV16-induced oropharyngeal and cervical cancer; ISA103 for PRAME-positive uveal melanoma and other tumors; ISA104 for chronic hepatitis B; ISA106 for SARS-CoV-2 in immunocompromised patients), plus MyISA® as a personalized neoantigen offering. The most advanced clinical data is the randomized Phase 2 OpcemISA trial (n=199), in which ISA101b plus a checkpoint inhibitor doubled objective response rate versus placebo plus checkpoint inhibitor in a predefined biomarker-defined subgroup of HPV16+ oropharyngeal cancer patients.

ISA does not sell commercial products and does not serve end consumers. Revenue is generated exclusively through licensing agreements and co-development partnerships that yield upfront fees, research and clinical milestone payments, and royalties on eventual net sales — exemplars include the Transgene license for tuberculosis vaccines, the Scancell collaboration on Modi-1/AMPLIVANT® combinations, and historical strategic co-development with Regeneron on ISA101b plus cemiplimab. The company's go-to-market is enterprise, partnership-driven business development aimed at pharmaceutical companies, academic medical centers, and cancer research institutions (e.g., MD Anderson Cancer Center, Erasmus MC, LUMC, Institut Gustave Roussy), with clinical trial sponsorships serving as the principal commercialization vector until regulatory approval enables commercial launch. Investors include Invest-NL, Regeneron, the European Investment Bank, and Cancer Focus Fund LP, with cumulative disclosed funding of approximately €59 million ($65 million equivalent) across rounds in 2013, 2019, 2021, and 2023.

Short descriptiontext

ISA Pharmaceuticals is a Dutch clinical-stage biotech (founded 2004) that develops synthetic long peptide (SLP®) and AMPLIVANT® therapeutic vaccines for HPV16-induced cancers, PRAME-positive tumors, chronic hepatitis B, and SARS-CoV-2, generating revenue via licensing and co-development partnerships with pharmaceutical companies and academic medical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic peptide vaccines, cancer immunotherapy, therapeutic cancer vaccines, peptide drug development, immuno-oncology research
Industry2 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

ISA Pharmaceuticals generates revenue through licensing agreements where partners gain rights to use its proprietary SLP® and AMPLIVANT® technologies. The company receives upfront fees, research and clinical milestone payments, and royalties on net sales of products resulting from these agreements. Example: license agreement with Transgene for TB vaccine development.

2Co-development and Milestone Payments
TypeLicensing Royalties
Description

Revenue from co-development partnerships where ISA collaborates on clinical development and receives milestone payments upon achievement of research, clinical, and regulatory objectives. Example: Cancer Focus Fund $5M investment supporting ISA103 clinical development at MD Anderson.

isa-pharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SLP®
Description

Synthetic Long Peptide immunotherapy technology platform

isa-pharma.com
+2 more records
Core offering1 text field

ISA Pharmaceuticals develops targeted, rationally designed synthetic long peptide (SLP®) immunotherapeutics for the treatment of cancer and persistent virus infections. Its portfolio includes ISA101b for HPV16-induced cancers, ISA103 for PRAME-positive tumors, ISA104 for chronic hepatitis B, ISA106 for SARS-CoV-2, and the personalized MyISA® neoantigen therapy, all powered by the proprietary SLP® peptide platform and AMPLIVANT® TLR-ligand adjuvant technology. The company advances its pipeline through co-development and licensing partnerships with pharmaceutical companies and academic medical centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Doubling of objective response rate (ORR) from 26.7% (placebo + CPI) to 51.9% (ISA101b + CPI) in predefined biomarker-defined subgroup of HPV16+ oropharyngeal cancer patients in OpcemISA Phase 2 trial (n=199)
+4 more records
Product overview1 text field

ISA Pharmaceuticals develops a portfolio of targeted, rationally designed immunotherapeutics for cancer and persistent virus infections. The core pipeline includes ISA101b (lead product for HPV16-induced cancers in late-stage development), ISA103 (PRAME-targeting immunotherapy for uveal melanoma), ISA104 (chronic Hepatitis B vaccine in Phase 1), and ISA106 (SARS-CoV-2 immunotherapy in late preclinical development). The company also offers MyISA for personalized neoantigen-based immunotherapy. All immunotherapeutics are powered by two proprietary technology platforms: SLP (Synthetic Long Peptide) technology for antigen delivery and immune activation, and AMPLIVANT TLR-ligand adjuvant technology for enhanced dendritic cell targeting and prolonged immune response.

Product and service4 records
1ISA101b (HPV16)
CategoryOncology therapeutic vaccine (HPV16-induced cancers)
Description

Therapeutic cancer vaccine targeting human papillomavirus type 16 (HPV16)-induced cancers including head and neck cancer and cervical cancer. Induces strong and specific T-cell immune responses to HPV16 E6 and E7 antigens and is being developed both as monotherapy and in combination with checkpoint inhibitors (anti-PD1 antibodies) and chemotherapy. Granted FDA Fast Track Designation (September 2021) for recurrent/metastatic HPV16-positive oropharyngeal cancer and US FDA Orphan Drug Designation for HPV16-positive cervical cancer.

2ISA103 (PRAME)
CategoryOncology therapeutic vaccine (PRAME-positive tumors)
Description

PRAME-targeting synthetic long peptide immunotherapy for the treatment of uveal melanoma and other PRAME-positive cancers including lung, breast, head & neck, kidney, melanoma, and neuroblastoma. Uses SLP® technology to generate strong and specific T-cell immune responses against the PRAME protein.

3ISA104 (HBV)
CategoryInfectious disease therapeutic vaccine (chronic hepatitis B)
Description

Therapeutic synthetic long peptide vaccine for chronic Hepatitis B virus infection designed to elicit a strong and specific T-cell immune response against HBV with the aim of achieving functional cure in chronically infected patients.

4ISA106 (SARS-CoV-2)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-31
Description

Erasmus MC is the sponsor of the HEB-PEP Phase 1 first-in-human study of ISA104 in chronic hepatitis B patients. The study is conducted in collaboration with the Gastroenterology & Hepatology department of Erasmus MC in Rotterdam and is co-funded by a PPP Allowance from Health~Holland, Top Sector Life Sciences & Health.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-27
Description

ISA is collaborating with LUMC and CHDR on the development of ISA106, an SLP therapy against SARS-CoV-2, with data presented at the CIMT Annual Meeting 2023 demonstrating robust T cell responses in preclinical studies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-04
Description

MD Anderson Cancer Center in Houston, Texas is conducting the Phase 1b/2 trial of ISA103 in uveal melanoma under Principal Investigator Dr. Sapna Patel, Director of MD Anderson's Uveal Melanoma Program. The trial will enroll 90 patients in a dose-finding phase followed by an expansion cohort.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-07-20
Description

ISA, in partnership with Erasmus MC, was awarded a TKI grant and expanded its clinical pipeline to include the ISA104 HBV program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-18
Description

Strategic immuno-oncology collaboration established in December 2017 for the development of ISA101b in combination with Regeneron's anti-PD-1 antibody cemiplimab (Libtayo®). Three clinical trials were conducted under this collaboration: OpcemISA (randomized Phase 2 in OPC), ProcemISA (Phase 2 in anti-PD1-resistant OPC), and a Phase 2 trial in cervical cancer. Regeneron has elected not to exercise its option on ISA101b.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-12-18
Description

Sanofi co-develops cemiplimab (Libtayo®) with Regeneron. ISA's clinical collaboration with Regeneron involves cemiplimab, making Sanofi an indirect partner in the ISA101b combination development program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

LUMC serves as a key strategic research collaborator for ISA Pharmaceuticals. Research teams from LUMC and ISA have co-authored multiple publications on SLP® technology, dendritic cell processing, and immunotherapy mechanisms. Prof. Sjoerd van der Burg from LUMC serves as Principal Investigator for multiple clinical trials.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination therapy, announced in February 2018.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

German mRNA therapeutics company developing cancer vaccines (CV8102, partnered products) and infectious disease vaccines. Competes with ISA in oncology immunotherapy with an alternative mRNA-based platform.

TypeEmerging player
Description

Swiss clinical-stage biotech developing neoantigen-based therapeutic cancer vaccines using viral vector platforms. Competes with ISA's MyISA® in the personalized cancer vaccine segment with overlapping clinical-stage assets in solid tumors.

TypeDirect peer
Description

Develops SPEAR T-cell therapies targeting PRAME (ADP-A2M4CD8) and other cancer-testis antigens. Direct competitor in the PRAME-positive cancer space (uveal melanoma, head & neck) where ISA103 is being developed, though with cell therapy rather than vaccine modality.

4Transgene
TypeDirect peer
Description

French biotech developing TG4001 therapeutic HPV vaccine and myvac® personalized cancer vaccines. Already an ISA licensing partner (TB vaccine agreement 2011) and operates as both collaborator and competitor in the HPV/therapeutic cancer vaccine category.

TypeBroad incumbent
Description

Develops mRNA-4157 (V940) personalized cancer vaccine partnered with Merck. As the leading mRNA oncology player with strong pharma backing, Moderna represents the most well-capitalized competitor in the cancer vaccine space where ISA operates.

6Hookipa Pharma
TypeDirect peer
Description

Develops HB-201/HB-202 arenavirus-based therapeutic vaccines for HPV16+ cancers, the same primary indication as ISA101b. Direct competitor in HPV-driven oropharyngeal and cervical cancer immunotherapy.

TypeEmerging player
Description

Develops HBV-targeted therapeutics including capsid inhibitors and RNAi agents aimed at functional cure of chronic Hepatitis B. Competes with ISA104 in the chronic HBV functional cure space using different therapeutic modalities.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutic cancer vaccines using the ATLAS neoantigen identification platform. Competes with ISA in personalized and targeted cancer immunotherapy, though focused on different antigens.

9BioNTech SE
TypeBroad incumbent
Description

Global leader in mRNA-based cancer immunotherapy with BNT122 (autogene cevumeran) personalized cancer vaccine partnered with Roche/Genentech. Competes with ISA's MyISA® in the personalized cancer vaccine space and represents the dominant platform competitor to peptide-based approaches.

TypeDirect peer
Description

UK-based developer of peptide-based therapeutic cancer vaccines (Modi-1, Modi-2) using ISA's AMPLIVANT® adjuvant under collaboration. Most direct technical peer given shared peptide vaccine + TLR ligand adjuvant approach and overlapping HPV/MAGE target focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ISA Pharmaceuticals

Cancer Immunotherapyisa-pharma.com

ISA Pharmaceuticals is a Dutch clinical-stage biotech (founded 2004) that develops synthetic long peptide (SLP®) and AMPLIVANT® therapeutic vaccines for HPV16-induced cancers, PRAME-positive tumors, chronic hepatitis B, and SARS-CoV-2, generating revenue via licensing and co-development partnerships with pharmaceutical companies and academic medical centers.

What ISA Pharmaceuticals does

ISA Pharmaceuticals B.V. is a privately held, clinical-stage Dutch biotechnology company founded in 2004 in Leiden (headquartered in Oegstgeest at the Leiden Bio Science Park) that develops rationally designed synthetic therapeutic vaccines for cancer and persistent viral infections. Its product engine rests on two proprietary platforms: the Synthetic Long Peptide (SLP®) technology — which delivers peptide vaccines covering the most immunogenic regions of target antigens and induces both CD4+ and CD8+ T-cell responses regardless of HLA type — and the AMPLIVANT® toll-like receptor (TLR) ligand adjuvant, which enhances dendritic cell targeting and is reported to be roughly 100-fold more potent than reference adjuvants. The clinical pipeline comprises four core programs (ISA101b for HPV16-induced oropharyngeal and cervical cancer; ISA103 for PRAME-positive uveal melanoma and other tumors; ISA104 for chronic hepatitis B; ISA106 for SARS-CoV-2 in immunocompromised patients), plus MyISA® as a personalized neoantigen offering. The most advanced clinical data is the randomized Phase 2 OpcemISA trial (n=199), in which ISA101b plus a checkpoint inhibitor doubled objective response rate versus placebo plus checkpoint inhibitor in a predefined biomarker-defined subgroup of HPV16+ oropharyngeal cancer patients.

ISA does not sell commercial products and does not serve end consumers. Revenue is generated exclusively through licensing agreements and co-development partnerships that yield upfront fees, research and clinical milestone payments, and royalties on eventual net sales — exemplars include the Transgene license for tuberculosis vaccines, the Scancell collaboration on Modi-1/AMPLIVANT® combinations, and historical strategic co-development with Regeneron on ISA101b plus cemiplimab. The company's go-to-market is enterprise, partnership-driven business development aimed at pharmaceutical companies, academic medical centers, and cancer research institutions (e.g., MD Anderson Cancer Center, Erasmus MC, LUMC, Institut Gustave Roussy), with clinical trial sponsorships serving as the principal commercialization vector until regulatory approval enables commercial launch. Investors include Invest-NL, Regeneron, the European Investment Bank, and Cancer Focus Fund LP, with cumulative disclosed funding of approximately €59 million ($65 million equivalent) across rounds in 2013, 2019, 2021, and 2023.

ISA Pharmaceuticals firmographics

Firmographics
Name
ISA Pharmaceuticals
Legal name
ISA Pharmaceuticals B.V.
Website
https://isa-pharma.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
ISA Pharmaceuticals is a Dutch clinical-stage biotech (founded 2004) that develops synthetic long peptide (SLP®) and AMPLIVANT® therapeutic vaccines for HPV16-induced cancers, PRAME-positive tumors, chronic hepatitis B, and SARS-CoV-2, generating revenue via licensing and co-development partnerships with pharmaceutical companies and academic medical centers.
Ownership category
akta.pro rank

ISA Pharmaceuticals industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Synthetic peptide vaccines
  • Cancer immunotherapy
  • Therapeutic cancer vaccines
  • Peptide drug development
  • Immuno-oncology research

Where ISA Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

ISA Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Royalty Revenue: ISA Pharmaceuticals generates revenue through licensing agreements where partners gain rights to use its proprietary SLP® and AMPLIVANT® technologies. The company receives upfront fees, research and clinical milestone payments, and royalties on net sales of products resulting from these agreements. Example: license agreement with Transgene for TB vaccine development.
  2. Co-development and Milestone Payments: Revenue from co-development partnerships where ISA collaborates on clinical development and receives milestone payments upon achievement of research, clinical, and regulatory objectives. Example: Cancer Focus Fund $5M investment supporting ISA103 clinical development at MD Anderson.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ISA Pharmaceuticals product offering

Product offering

Core offering

ISA Pharmaceuticals develops targeted, rationally designed synthetic long peptide (SLP®) immunotherapeutics for the treatment of cancer and persistent virus infections. Its portfolio includes ISA101b for HPV16-induced cancers, ISA103 for PRAME-positive tumors, ISA104 for chronic hepatitis B, ISA106 for SARS-CoV-2, and the personalized MyISA® neoantigen therapy, all powered by the proprietary SLP® peptide platform and AMPLIVANT® TLR-ligand adjuvant technology. The company advances its pipeline through co-development and licensing partnerships with pharmaceutical companies and academic medical centers.

Product overview

ISA Pharmaceuticals develops a portfolio of targeted, rationally designed immunotherapeutics for cancer and persistent virus infections. The core pipeline includes ISA101b (lead product for HPV16-induced cancers in late-stage development), ISA103 (PRAME-targeting immunotherapy for uveal melanoma), ISA104 (chronic Hepatitis B vaccine in Phase 1), and ISA106 (SARS-CoV-2 immunotherapy in late preclinical development). The company also offers MyISA for personalized neoantigen-based immunotherapy. All immunotherapeutics are powered by two proprietary technology platforms: SLP (Synthetic Long Peptide) technology for antigen delivery and immune activation, and AMPLIVANT TLR-ligand adjuvant technology for enhanced dendritic cell targeting and prolonged immune response.

Differentiator

Problem solved

Functional benefit

Brands

  • SLP®: Synthetic Long Peptide immunotherapy technology platform
  • AMPLIVANT®
  • MyISA®

Products and services

  • ISA101b (HPV16) Therapeutic cancer vaccine targeting human papillomavirus type 16 (HPV16)-induced cancers including head and neck cancer and cervical cancer. Induces strong and specific T-cell immune responses to HPV16 E6 and E7 antigens and is being developed both as monotherapy and in combination with checkpoint inhibitors (anti-PD1 antibodies) and chemotherapy. Granted FDA Fast Track Designation (September 2021) for recurrent/metastatic HPV16-positive oropharyngeal cancer and US FDA Orphan Drug Designation for HPV16-positive cervical cancer.
  • ISA103 (PRAME) PRAME-targeting synthetic long peptide immunotherapy for the treatment of uveal melanoma and other PRAME-positive cancers including lung, breast, head & neck, kidney, melanoma, and neuroblastoma. Uses SLP® technology to generate strong and specific T-cell immune responses against the PRAME protein.
  • ISA104 (HBV) Therapeutic synthetic long peptide vaccine for chronic Hepatitis B virus infection designed to elicit a strong and specific T-cell immune response against HBV with the aim of achieving functional cure in chronically infected patients.
  • ISA106 (SARS-CoV-2)

Quantifiable outcome

  • Doubling of objective response rate (ORR) from 26.7% (placebo + CPI) to 51.9% (ISA101b + CPI) in predefined biomarker-defined subgroup of HPV16+ oropharyngeal cancer patients in OpcemISA Phase 2 trial (n=199)
  • +4 more outcomes

Companies that use ISA Pharmaceuticals

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

ISA Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

ISA Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Erasmus Medical Center RotterdamcoreStrategic or Co-development Partner · 31 August 2023Erasmus MC is the sponsor of the HEB-PEP Phase 1 first-in-human study of ISA104 in chronic hepatitis B patients. The study is conducted in collaboration with the Gastroenterology & Hepatology department of Erasmus MC in Rotterdam and is co-funded by a PPP Allowance from Health~Holland, Top Sector Life Sciences & Health.
  • Leiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR)minorStrategic or Co-development Partner · 27 April 2023ISA is collaborating with LUMC and CHDR on the development of ISA106, an SLP therapy against SARS-CoV-2, with data presented at the CIMT Annual Meeting 2023 demonstrating robust T cell responses in preclinical studies.
  • MD Anderson Cancer CentercoreStrategic or Co-development Partner · 4 January 2023MD Anderson Cancer Center in Houston, Texas is conducting the Phase 1b/2 trial of ISA103 in uveal melanoma under Principal Investigator Dr. Sapna Patel, Director of MD Anderson's Uveal Melanoma Program. The trial will enroll 90 patients in a dose-finding phase followed by an expansion cohort.
  • Erasmus MCminorStrategic or Co-development Partner · 20 July 2021ISA, in partnership with Erasmus MC, was awarded a TKI grant and expanded its clinical pipeline to include the ISA104 HBV program.
  • Regeneron PharmaceuticalscoreStrategic or Co-development Partner · 18 December 2017Strategic immuno-oncology collaboration established in December 2017 for the development of ISA101b in combination with Regeneron's anti-PD-1 antibody cemiplimab (Libtayo®). Three clinical trials were conducted under this collaboration: OpcemISA (randomized Phase 2 in OPC), ProcemISA (Phase 2 in anti-PD1-resistant OPC), and a Phase 2 trial in cervical cancer. Regeneron has elected not to exercise its option on ISA101b.
  • SanofiminorStrategic or Co-development Partner · 18 December 2017Sanofi co-develops cemiplimab (Libtayo®) with Regeneron. ISA's clinical collaboration with Regeneron involves cemiplimab, making Sanofi an indirect partner in the ISA101b combination development program.
  • Leiden University Medical Center (LUMC)coreStrategic or Co-development PartnerLUMC serves as a key strategic research collaborator for ISA Pharmaceuticals. Research teams from LUMC and ISA have co-authored multiple publications on SLP® technology, dendritic cell processing, and immunotherapy mechanisms. Prof. Sjoerd van der Burg from LUMC serves as Principal Investigator for multiple clinical trials.
  • Scancell Holdings plcminorStrategic or Co-development PartnerCollaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination therapy, announced in February 2018.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

ISA Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • CureVac: German mRNA therapeutics company developing cancer vaccines (CV8102, partnered products) and infectious disease vaccines. Competes with ISA in oncology immunotherapy with an alternative mRNA-based platform.
  • Nouscom: Swiss clinical-stage biotech developing neoantigen-based therapeutic cancer vaccines using viral vector platforms. Competes with ISA's MyISA® in the personalized cancer vaccine segment with overlapping clinical-stage assets in solid tumors.
  • Arbutus Biopharma: Develops HBV-targeted therapeutics including capsid inhibitors and RNAi agents aimed at functional cure of chronic Hepatitis B. Competes with ISA104 in the chronic HBV functional cure space using different therapeutic modalities.
  • Genocea Biosciences: Clinical-stage biotech developing therapeutic cancer vaccines using the ATLAS neoantigen identification platform. Competes with ISA in personalized and targeted cancer immunotherapy, though focused on different antigens.

Direct peers

  • Adaptimmune Therapeutics: Develops SPEAR T-cell therapies targeting PRAME (ADP-A2M4CD8) and other cancer-testis antigens. Direct competitor in the PRAME-positive cancer space (uveal melanoma, head & neck) where ISA103 is being developed, though with cell therapy rather than vaccine modality.
  • Transgene: French biotech developing TG4001 therapeutic HPV vaccine and myvac® personalized cancer vaccines. Already an ISA licensing partner (TB vaccine agreement 2011) and operates as both collaborator and competitor in the HPV/therapeutic cancer vaccine category.
  • Hookipa Pharma: Develops HB-201/HB-202 arenavirus-based therapeutic vaccines for HPV16+ cancers, the same primary indication as ISA101b. Direct competitor in HPV-driven oropharyngeal and cervical cancer immunotherapy.
  • Scancell Holdings: UK-based developer of peptide-based therapeutic cancer vaccines (Modi-1, Modi-2) using ISA's AMPLIVANT® adjuvant under collaboration. Most direct technical peer given shared peptide vaccine + TLR ligand adjuvant approach and overlapping HPV/MAGE target focus.

Broad incumbents

  • Moderna: Develops mRNA-4157 (V940) personalized cancer vaccine partnered with Merck. As the leading mRNA oncology player with strong pharma backing, Moderna represents the most well-capitalized competitor in the cancer vaccine space where ISA operates.
  • BioNTech SE: Global leader in mRNA-based cancer immunotherapy with BNT122 (autogene cevumeran) personalized cancer vaccine partnered with Roche/Genentech. Competes with ISA's MyISA® in the personalized cancer vaccine space and represents the dominant platform competitor to peptide-based approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ISA Pharmaceuticals social profiles

Digital presence

ISA Pharmaceuticals compliance and trust

Trust signal

Compliance4 records

ISA Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ISA Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

ISA Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ISA Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ISA Pharmaceuticals

What does ISA Pharmaceuticals do?

ISA Pharmaceuticals develops targeted, rationally designed synthetic long peptide (SLP®) immunotherapeutics for the treatment of cancer and persistent virus infections. Its portfolio includes ISA101b for HPV16-induced cancers, ISA103 for PRAME-positive tumors, ISA104 for chronic hepatitis B, ISA106 for SARS-CoV-2, and the personalized MyISA® neoantigen therapy, all powered by the proprietary SLP® peptide platform and AMPLIVANT® TLR-ligand adjuvant technology. The company advances its pipeline through co-development and licensing partnerships with pharmaceutical companies and academic medical centers.

Is ISA Pharmaceuticals a public or private company?

ISA Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was ISA Pharmaceuticals founded?

ISA Pharmaceuticals was founded in 2004. It employs 11 to 50 people.

Where is ISA Pharmaceuticals based?

ISA Pharmaceuticals is headquartered in Leiden, Netherlands, in the Europe region.

How does ISA Pharmaceuticals make money?

Two revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are co-development and Milestone Payments.

Who are ISA Pharmaceuticals's main competitors?

Emerging players on record are CureVac, Nouscom, Arbutus Biopharma and Genocea Biosciences. Direct peers are Adaptimmune Therapeutics, Transgene, Hookipa Pharma and Scancell Holdings. Broad incumbents are Moderna and BioNTech SE.

Does ISA Pharmaceuticals have an API?

No public API is recorded for ISA Pharmaceuticals.

What industry is ISA Pharmaceuticals in?

ISA Pharmaceuticals's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Fact.MRHPV-Driven Tumor Growth Suppressor Market to Reach $3.0Bn by 2036 as Cervical Cancer Leads Applications: Fact.MRMarket research firm Fact.MR projects the global HPV-driven tumor growth suppressor market will expand from $1.3 billion in 2026 to $3.0 billion by 2036, representing an 8.8% CAGR and $1.7 billion in absolute added demand over the decade. E6/E7 Oncoprotein Inhibitors lead the therapeutic approach segment at 25%, cervical cancer leads indications at 25%, and p53 Restoration leads mechanisms of action at 25%, with Germany (11.9%), Brazil (11.0%), and the United States (10.1%) posting the strongest country-level growth rates. Multiple pharmaceutical companies are actively developing HPV-targeted therapies including BioNTech, Transgene, ISA Pharmaceuticals, Precigen, PDS Biotechnology, Hookipa Pharma, and Merck & Co., though the primary development barrier remains proving that pathway correction reduces tumor growth beyond laboratory markers.PR NewswireHPV16+ Cancer Treatment Market is Expected to Showcase Significant Growth by 2034, Assesses DelveInsight | Key Companies in the Market - Nykode Therapeutics, Roche, ISA Pharmaceuticals, Regeneron, TraDelveInsight released a market insights report projecting the HPV16+ cancer market in the 7MM (United States, EU4, UK, and Japan) to grow at a significant CAGR through 2034, driven by pipeline drug candidates and improved screening and diagnosis. In December 2023, ISA Pharmaceuticals announced positive Phase II data for ISA101b combined with LIBTAYO (cemiplimab) showing a doubling of objective response rate (51.9% vs 26.7%) in advanced oropharyngeal cancer patients, with improved overall survival. Key companies including Nykode Therapeutics, ISA Pharmaceuticals, Transgene, and Regeneron are actively developing novel HPV16+ cancer therapies such as VB10.16, ISA101b, and TG4001, which are expected to reshape the treatment landscape.PR NewswireFirst Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 StudyISA Pharmaceuticals B.V. announced that the first patient has been dosed in the HEB-PEP first-in-human Phase 1 study of ISA104, a novel immunotherapy designed to achieve functional cure in chronic Hepatitis B patients. The dose escalation study is being conducted at the Liver Unit of Erasmus Medical Center in Rotterdam, the Netherlands, and will investigate the safety, tolerability, and efficacy of different doses versus placebo. ISA104 is the company's latest pipeline program to enter clinical development, building on ISA's Synthetic Long Peptide (SLP®) technology which has previously demonstrated effectiveness in HPV16-infected patients.PR NewswireThe combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapyISA Pharmaceuticals presented early clinical data at the ASCO 2023 annual meeting showing that a combination of its therapeutic cancer vaccine ISA101b and Regeneron's anti-PD-1 drug Libtayo (cemiplimab) produced an overall response rate of 15.4% and a 6-month disease control rate of 26.9% in 26 patients with HPV16-positive head and neck cancer that had progressed on prior anti-PD1 therapy.PR NewswireISA Pharmaceuticals to Present First Clinical Trial Data from the Phase II Study of ISA101b and Libtayo® (cemiplimab) Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023ISA Pharmaceuticals announced it will present first clinical data from the ProcemISA Phase II trial combining its ISA101b immunotherapy with Regeneron's Libtayo (cemiplimab) for patients with recurrent metastatic HPV16-positive head and neck cancer who progressed on prior anti-PD1 therapy. Dr. Anthony Kong will present the findings at the ASCO Annual Meeting on June 5, 2023, with full trial results expected in mid-2024. The FDA granted Fast Track designation to ISA101b in September 2021 for this indication, which represents an area of high unmet medical need.PR NewswireISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual MeetingISA Pharmaceuticals announced it will present pre-clinical data on its T cell-inducing SLP therapy ISA106 against SARS-CoV-2 at the CIMT Annual Meeting in Mainz, Germany on May 4, 2023, in collaboration with Leiden University Medical Center and Centre for Human Drug Research. The data demonstrates that ISA106 adjuvanted SLP therapy elicits robust T cell responses in mice and reactivates memory T cell responses in peripheral blood mononuclear cells from convalescent donors. The findings support further development of ISA106 to provide improved protection against SARS-CoV-2 for individuals with spontaneous or therapy-induced B cell deficiencies.PR NewswireISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal MelanomaCancer Focus Fund announced a $5 million investment in ISA Pharmaceuticals to fund a first-in-human Phase 1b/2 clinical trial of ISA103, a PRAME-targeting immunotherapy for uveal melanoma, a rare ocular cancer. The trial will be conducted at MD Anderson Cancer Center, enrolling 90 patients to test ISA103 in combination with standard checkpoint blocker immunotherapies. ISA Pharmaceuticals has previously demonstrated proof-of-concept with its lead product ISA101b in HPV-induced cancers.PR NewswireISA Pharmaceuticals Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal CancerISA Pharmaceuticals announced the completion of patient enrolment for its Phase 2 clinical trial, OpcemISA, investigating the efficacy and safety of ISA101b combined with checkpoint inhibitor therapy for HPV16-induced oropharyngeal cancer. This milestone is part of a collaborative development program with Regeneron, with top-line interim results expected in the third quarter of 2023. The trial involves 194 patients and aims to evaluate overall response rate and survival outcomes for this difficult-to-treat cancer.ZapierISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapyISA Pharmaceuticals published a phase 1 study of its Amplivant adjuvant conjugated to HPV16 SLP vaccine in patients with HPV16-positive (pre-)malignancies. The study showed a favorable safety profile and strong T cell immunity with only two doses, and dose escalation increased systemic T cell responses.